Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis

Gonçalves, Mauro; Barbosa, Egberto Reis; Zambon, A A; Marchiori, Paulo Eurípedes

doi:10.1590/s0004-282x1999000400024

Cited by 14 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with BoNT may exacerbate symptoms of coexistent neuromuscular diseases ( 89 , 90 ) or unmask subclinical cases ( 91 , 92 ). Myasthenia gravis, amyotrophic lateral sclerosis, and Lambert–Eaton diseases are reported as contraindications to BoNTs treatment in the respective SPCs, although cases of safe CD treatment in patients with myasthenia or amyotrophic lateral sclerosis have occasionally been reported ( 93 , 94 ).…”

Section: Resultsmentioning

confidence: 99%

Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin

et al. 2017

View full text Add to dashboard Cite

Cervical dystonia (CD) is the most frequent form of focal dystonia. Symptoms often result in pain and functional disability. Local injections of botulinum neurotoxin are currently the treatment of choice for CD. Although this treatment has proven effective and is widely applied worldwide, many issues still remain open in the clinical practice. We performed a systematic review of the literature on botulinum toxin treatment for CD based on a question-oriented approach, with the aim to provide practical recommendations for the treating clinicians. Key questions from the clinical practice were explored. Results suggest that while the beneficial effect of botulinum toxin treatment on different aspects of CD is well established, robust evidence is still missing concerning some practical aspects, such as dose equivalence between different formulations, optimal treatment intervals, treatment approaches, and the use of supportive techniques including electromyography or ultrasounds. Established strategies to prevent or manage common side effects (including excessive muscle weakness, pain at injection site, dysphagia) and potential contraindications to this treatment (pregnancy and lactation, use of anticoagulants, neurological comorbidities) should also be further explored.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin

et al. 2017

View full text Add to dashboard Cite

show abstract

“…One case study describes a 49-year-old woman with both MG and cervical dystonia. 4 The individual was treated for her dystonia using Botox, with no observed flare in her MG symptoms. Her MG did not progress following the Botox treatment.…”

Section: Discussionmentioning

confidence: 99%

The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis

Wright¹,

Civitarese²,

Baverstock

2016

CUAJ

View full text Add to dashboard Cite

show abstract

“…for cervical dystonia). [182,183] Although pregnancy and active nursing are considered absolute contraindications to BTX-A (pregnancy category C), pregnant and nursing women have been inadvertently treated with BTX-A without ill effects; [126,184] however, no studies have been specifically designed to demonstrate the safety of BTX-A in this population, nor in individuals of either sex aged ‡65 years. It is thus advisable to postpone elective BTX-A treatment in pregnant or nursing patients; in contrast, those aged ‡65 years are treated routinely without increased concern.…”

Section: General Considerationsmentioning

confidence: 99%

Botulinum Toxin for Hyperhidrosis

Grunfeld

Murray

Solish

2009

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Primary focal hyperhidrosis is a disorder of idiopathic excessive sweating that typically affects the axillae, palms, soles, and face. The disorder, which affects up to 2.8% of the US population, is associated with considerable physical, psychosocial, and occupational impairments. Current therapeutic strategies include topical aluminum salts, tap-water iontophoresis, oral anticholinergic agents, local surgical approaches, and sympathectomies. These treatments, however, have been limited by a relatively high incidence of adverse effects and complications. Non-surgical treatment complications are typically transient, whereas those of surgical therapies may be permanent and significant. Recently, considerable evidence suggests that botulinum toxin type A (BTX-A) injections into hyperhidrotic areas can considerably reduce focal sweating in multiple areas without major adverse effects. BTX-A has therefore shown promise as a potential replacement for more invasive treatments after topical aluminum salts have failed. This article reviews the epidemiology, diagnosis, and management of primary focal hyperhidrosis, with an emphasis on recent research evidence supporting the use of BTX-A injections for this indication.

show abstract

Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis

Cited by 14 publications

References 5 publications

Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin

Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin

The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis

Botulinum Toxin for Hyperhidrosis

Contact Info

Product

Resources

About